1-((6-Chloropyridin-3-yl)sulfonyl)-4-methylpiperazine

Catalog No. :
ACEGVA745
CAS No. :
64614-53-5
Molecular Formula :
C10H14ClN3O2S
Molecular Weight :
275.76

IUPAC Name:1-((6-chloropyridin-3-yl)sulfonyl)-4-methylpiperazine

1-((6-Chloropyridin-3-yl)sulfonyl)-4-methylpiperazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg97%$113.00Login to see priceInquiryInquiry
250mg97%$402.00Login to see priceInquiryInquiry
1g97%$533.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-((6-Chloropyridin-3-yl)sulfonyl)-4-methylpiperazine
IUPAC Name1-((6-chloropyridin-3-yl)sulfonyl)-4-methylpiperazine
MDL No.MFCD03988227
Molecular FormulaC10H14ClN3O2S
Molecular Weight275.76
SMILESCN1CCN(S(=O)(C2=CC=C(Cl)N=C2)=O)CC1
InChI KeyKJNDIWBXKRQJHC-UHFFFAOYSA-N
SynonymPiperazine, 1-[(6-chloro-3-pyridinyl)sulfonyl]-4-methyl-;1-[(6-chloropyridin-3-yl)sulfonyl]-4-methylpiperazine1-[(6-chloropyridin-3-yl)sulphonyl]-4-methylpiperazine
CAS No.64614-53-5

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACEGVA745 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACJACD865 route compound structure diagram
    ACJACD86534352-59-5 In Stock
  2. Plus
  3. ACJYCO531 route compound structure diagram
    ACJYCO5316684-39-5 In Stock
  4. Then
  5. ACEGVA745 route product structure diagram
    ACEGVA74564614-53-5
Inquiry

2. ACEGVA745 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACEGVA745 route product structure diagram
    ACEGVA74564614-53-5
Inquiry

Comments (0)